NYSE:BHVN - Biohaven Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biohaven Pharmaceutical Holding Co Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $54.50 -1.47 (-2.63 %) (As of 01/26/2020 04:00 PM ET) Add Compare Today's Range$53.39Now: $54.50▼$56.6750-Day Range$51.12MA: $54.28▼$57.2952-Week Range$34.06Now: $54.50▼$67.86Volume731,764 shsAverage Volume710,185 shsMarket Capitalization$2.85 billionP/E RatioN/ADividend YieldN/ABeta0.43 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CUSIPN/A CIK1689813 Webhttp://www.biohavenpharma.com/ Phone203-404-0410Debt Debt-to-Equity RatioN/A Current Ratio8.96 Quick Ratio8.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.74 per share Price / Book14.57Profitability EPS (Most Recent Fiscal Year)($6.15) Net Income$-240,920,000.00 Net MarginsN/A Return on Equity-237.81% Return on Assets-89.87%Miscellaneous Employees63 Outstanding Shares52,240,000Market Cap$2.85 billion Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive BHVN News and Ratings via Email Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter. BHVN Rates by TradingView Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions What is Biohaven Pharmaceutical's stock symbol? Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN." How were Biohaven Pharmaceutical's earnings last quarter? Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) posted its earnings results on Friday, November, 1st. The company reported ($2.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.57) by $0.47. View Biohaven Pharmaceutical's Earnings History. When is Biohaven Pharmaceutical's next earnings date? Biohaven Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Biohaven Pharmaceutical. What price target have analysts set for BHVN? 12 brokerages have issued 1-year price targets for Biohaven Pharmaceutical's shares. Their forecasts range from $50.00 to $100.00. On average, they expect Biohaven Pharmaceutical's stock price to reach $73.55 in the next year. This suggests a possible upside of 34.9% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical. What is the consensus analysts' recommendation for Biohaven Pharmaceutical? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical. Has Biohaven Pharmaceutical been receiving favorable news coverage? Media stories about BHVN stock have been trending extremely negative this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biohaven Pharmaceutical earned a news sentiment score of -4.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Biohaven Pharmaceutical. Are investors shorting Biohaven Pharmaceutical? Biohaven Pharmaceutical saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 6,230,000 shares, a decrease of 6.9% from the December 15th total of 6,690,000 shares. Based on an average daily trading volume, of 613,600 shares, the days-to-cover ratio is presently 10.2 days. Currently, 14.5% of the shares of the company are short sold. View Biohaven Pharmaceutical's Current Options Chain. Who are some of Biohaven Pharmaceutical's key competitors? Some companies that are related to Biohaven Pharmaceutical include Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Amarin (AMRN), Dr.Reddy's Laboratories (RDY), Horizon Therapeutics (HZNP), The Medicines (MDCO), ACADIA Pharmaceuticals (ACAD) and Reata Pharmaceuticals (RETA). What other stocks do shareholders of Biohaven Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Netflix (NFLX), Global Blood Therapeutics (GBT), Roku (ROKU), Sarepta Therapeutics (SRPT) and ACADIA Pharmaceuticals (ACAD). Who are Biohaven Pharmaceutical's key executives? Biohaven Pharmaceutical's management team includes the folowing people: Dr. Vladimir Coric, CEO & Director (Age 48)Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 55)Dr. Charles Conway, Chief Scientific Officer (Age 57)Mr. Clifford Bechtold, Chief Operating OfficerMr. Matthew DeLawder, Director of Accounting When did Biohaven Pharmaceutical IPO? (BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Who are Biohaven Pharmaceutical's major shareholders? Biohaven Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.24%), Columbus Circle Investors (0.05%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Canton Hathaway LLC (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical. Which major investors are buying Biohaven Pharmaceutical stock? BHVN stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Columbus Circle Investors, Canton Hathaway LLC, Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical. How do I buy shares of Biohaven Pharmaceutical? Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Biohaven Pharmaceutical's stock price today? One share of BHVN stock can currently be purchased for approximately $54.50. How big of a company is Biohaven Pharmaceutical? Biohaven Pharmaceutical has a market capitalization of $2.85 billion. The company earns $-240,920,000.00 in net income (profit) each year or ($6.15) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.View Additional Information About Biohaven Pharmaceutical. What is Biohaven Pharmaceutical's official website? The official website for Biohaven Pharmaceutical is http://www.biohavenpharma.com/. How can I contact Biohaven Pharmaceutical? Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410. MarketBeat Community Rating for Biohaven Pharmaceutical (NYSE BHVN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 283 (Vote Outperform)Underperform Votes: 325 (Vote Underperform)Total Votes: 608MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: What is diluted earnings per share (Diluted EPS)?
